Iridex Corp. Company Profile (NASDAQ:IRIX)

Analyst Ratings

Consensus Ratings for Iridex Corp. (NASDAQ:IRIX) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.50 (29.06% downside)

Analysts' Ratings History for Iridex Corp. (NASDAQ:IRIX)
Show:
DateFirmActionRatingPrice TargetActions
1/26/2016Singular ResearchInitiated CoverageBuy$11.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Iridex Corp. (NASDAQ:IRIX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016Q216$0.01$11.90 millionListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2016Q116$0.04$0.01$11.88 million$11.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q415$0.04$0.04$11.80 million$12.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315$0.04$10.10 million$9.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.07)$10.60 million$9.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115$0.02$10.30 million$10.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2015Q414$0.97$10.60 million$11.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q1$0.06$0.05$8.90 million$10.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q4$0.04$0.04ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Iridex Corp. (NASDAQ:IRIX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Iridex Corp. (NASDAQ:IRIX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Iridex Corp. (NASDAQ:IRIX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/6/2016Ronald SteckelVPSell625$13.52$8,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2016Ronald SteckelVPSell4,583$12.81$58,708.23View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2016Ronald SteckelVPSell12,000$10.45$125,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2015William M MooreCEOBuy10,000$9.83$98,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2015Associates & Paragon A ParagonMajor ShareholderBuy52,042$7.05$366,896.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015Associates & Paragon A ParagonMajor ShareholderBuy11,866$6.95$82,468.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2015Associates & Paragon A ParagonMajor ShareholderBuy10,304$6.81$70,170.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2015Ronald SteckelVPSell1,875$6.80$12,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2015Associates & Paragon A ParagonMajor ShareholderBuy20,651$7.16$147,861.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2015James H. MackanessCFOSell2,373$7.15$16,966.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2015Ronald SteckelVPSell1,751$7.14$12,502.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015James H. MackanessCFOSell2,627$7.10$18,651.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015James H. MackanessCFOSell2,235$7.05$15,756.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2015James H MackanessCFOSell7,765$6.99$54,277.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2015Ronald SteckelVPSell1,458$7.00$10,206.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/24/2015Associates & Paragon A ParagonMajor ShareholderBuy40,403$7.01$283,225.03View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2015Ronald SteckelVPSell1,666$8.77$14,610.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2015James H MackanessCFOSell2,000$9.80$19,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Ronald SteckelVPSell1,667$9.33$15,553.11View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2015Ronald SteckelVPSell1,447$9.79$14,166.13View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/17/2015Ronald SteckelVPSell1,667$9.86$16,436.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Ronald SteckelVPSell11,358$10.08$114,488.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015Ronald SteckelVPSell1,250$10.03$12,537.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015Ronald SteckelVPSell1,650$9.79$16,153.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015Ronald SteckelVPSell1,650$9.03$14,899.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2014Ronald SteckelVPSell1,650$8.52$14,058.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014Ronald SteckelVPSell1,650$8.28$13,662.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2014William M MooreDirectorBuy5,000$7.79$38,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/12/2014Catalyst Fund Ix L.P BluelineDirectorBuy17,237$8.11$139,792.07View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014Catalyst Fund Ix L.P BluelineDirectorBuy12,798$8.02$102,639.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2014Catalyst Fund Ix L.P BluelineDirectorBuy8,432$7.99$67,371.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2014Catalyst Fund Ix L.P BluelineDirectorBuy4,272$7.92$33,834.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/22/2014James B HawkinsDirectorSell600$8.03$4,818.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Ronald SteckelVPSell1,650$8.00$13,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014James B HawkinsDirectorSell14,400$8.10$116,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014James B HawkinsDirectorSell2,714$8.08$21,929.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014James B HawkinsDirectorSell9,786$8.11$79,364.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Garrett A GarrettsonDirectorSell2,810$8.30$23,323.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/31/2014Ronald SteckelVPSell761$8.00$6,088.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/21/2014James H MackanessCFOSell1,000$7.62$7,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014James H MackanessCFOSell2,000$8.24$16,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014Ronald SteckelVPSell1,650$8.20$13,530.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2014Catalyst Fund Ix L.P BluelineDirectorBuy7,390$8.32$61,484.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2014William M MooreCEOBuy5,000$8.48$42,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014James H MackanessCFOSell3,000$8.73$26,190.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Ronald SteckelVPSell1,650$8.82$14,553.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2014William M MooreCEOBuy5,000$8.40$42,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2014James H MackanessCFOSell4,000$8.74$34,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/17/2014Ronald SteckelVPSell1,650$8.88$14,652.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014James H MackanessCFOSell4,000$9.03$36,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2014Ronald SteckelVPSell1,650$9.07$14,965.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Ronald SteckelVPSell1,650$8.60$14,190.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/17/2014Ronald SteckelVPSell1,650$10.42$17,193.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2013Ronald SteckelVPSell1,650$8.56$14,124.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013James H MackanessCFOSell10,000$10.52$105,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/6/2013Ruediger Naumann-EtienneDirectorBuy3,600$5.99$21,564.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/9/2013William M MooreCEOBuy10,000$5.88$58,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2013Eduardo AriasVPSell22,768$5.43$123,630.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2013James H MackanessCFOSell19,862$4.58$90,967.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2013Eduardo AriasVPSell4,532$5.39$24,427.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2013James H MackanessCFOSell10,568$5.38$56,855.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2013James H MackanessCFOSell1,400$5.30$7,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013Eduardo AriasVPSell1,000$5.61$5,610.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013James H MackanessCFOSell1,200$5.61$6,732.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2013Eduardo AriasVPSell2,400$5.38$12,912.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2013James H MackanessCFOSell6,970$5.36$37,359.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2013William M MooreCEOBuy2,000$5.42$10,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2013Eduardo AriasVPSell10,000$6.30$63,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2013Ruediger Naumann-EtienneDirectorBuy2,400$4.80$11,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2013William M MooreCEOBuy10,000$4.66$46,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/6/2012William M MooreCEOBuy10,000$3.76$37,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2012Catalyst Fund Ix L.P BluelineMajor ShareholderBuy60,900$3.19$194,271.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Iridex Corp. (NASDAQ:IRIX)
DateHeadline
07/28/16 03:18 PMIRIDEX Announces Second Quarter 2016 Conference Call and Release Date - [at noodls] - MOUNTAIN VIEW, Calif., July 28, 2016 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its second quarter 2016 financial results after the market closes on Thursday, ...
07/21/16 01:09 PMETF’s with exposure to IRIDEX Corp. : July 21, 2016 -
07/11/16 03:17 PMIRIDEX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agre -
07/11/16 06:03 AMIRIDEX Announces Atabak Mokari Will Be Chief Financial Officer And VP Corporate Development - [at noodls] - MOUNTAIN VIEW, Calif., July 11, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that Atabak Mokari, 39, will join the Company as Chief Financial Officer and Vice President of Corporate ...
06/21/16 03:17 PMIRIDEX CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/02/16 03:35 PMIRIDEX to Present at the Singular Research 11th Annual Best of the Uncovereds Spring Select Conference - [at noodls] - MOUNTAIN VIEW, Calif., June 2, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX), a leading global provider of innovative laser systems, delivery devices and consumables in ophthalmology, today announced ...
05/20/16 10:43 AMInvestors’ Pick for May 20 – PQ, AQMS, BRC, IRIX, USMD, DWSN, UNB - IRIDEX Corporation (IRIX) posted a new high of 13.99 above a previous 52 week ... The company traded at $18.20 + 1.20 (7.06 pct) on 44,577 total stock volume. Dawson Geophysical Co. (DWSN) posted a new high of 6.50 above a previous 52 week high of 6.24.
05/11/16 10:57 AMIRIDEX Corp. :IRIX-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/10/16 06:18 AMIRIDEX Announces Cyclo G6™ with MicroPulse® P3 Clinical Data Presented at ARVO and ASCRS Annual Meetings - [at noodls] - MOUNTAIN VIEW, Calif., May 10, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX), a leading global provider of innovative laser systems, delivery devices and consumables in ophthalmology, today announced ...
05/05/16 05:24 PMIridex posts 1Q profit -
05/05/16 03:05 PMIRIDEX Reports 2016 First Quarter Results - [PR Newswire] - MOUNTAIN VIEW, Calif., May 5, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 2, 2016. Revenues were $11.9 million for the first ...
05/05/16 06:07 AMQ1 2016 IRIDEX Corp Earnings Release - After Market Close -
04/28/16 03:36 PMIRIDEX Announces First Quarter 2016 Conference Call and Release Date - [at noodls] - MOUNTAIN VIEW, Calif., April 28, 2016 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its first quarter 2016 financial results after the market closes on Thursday, ...
03/31/16 04:20 PMIRIDEX CORP Files SEC form 10-K, Annual Report -
03/22/16 03:31 PMIRIDEX Gains Patent Approvals Covering TxCell™-Guided MicroPulse® Laser Therapy; Predictably Enables Faster, Durable Treatments for Glaucoma and Retinal Diseases - [at noodls] - MOUNTAIN VIEW, Calif., March 22, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX), a leading global provider of innovative laser systems, delivery devices and consumables in ophthalmology, announced ...
03/22/16 03:07 PM4:07 pm IRIDEX gains 2 patent approvals covering TXcell-guided micropulse laser therapy, enables treatments for glaucoma and retinal diseases -
03/10/16 12:54 PMETF’s with exposure to IRIDEX Corp. : March 10, 2016 -
03/09/16 11:03 AMIRIDEX Corp. :IRIX-US: Earnings Analysis: 2015 By the Numbers -
03/07/16 04:17 PMIRIDEX CORP Files SEC form 8-K, Change in Directors or Principal Officers -
03/04/16 01:47 PMEdited Transcript of IRIX earnings conference call or presentation 3-Mar-16 10:00pm GMT -
03/03/16 04:20 PMIridex posts 4Q profit -
03/03/16 04:00 PMIRIDEX Corp Earnings Call scheduled for 5:00 pm ET today -
03/03/16 03:05 PMIRIDEX Reports 2015 Fourth Quarter, Full Year Results - [PR Newswire] - MOUNTAIN VIEW, Calif., March 3, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended January 2, 2016. Revenues were $12.1 million ...
03/03/16 06:07 AMQ4 2015 IRIDEX Corp Earnings Release - After Market Close -
02/16/16 05:30 AMIRIDEX Receives CE Mark for Cyclo G6™ Laser System for the Treatment of Multiple Stages of Glaucoma - [PR Newswire] - MOUNTAIN VIEW, Calif., Feb. 16, 2016 /PRNewswire/ -- IRIDEX Corporation (IRIX), a leading global provider of innovative laser systems, delivery devices and consumables in ophthalmology, today announced that it has received its CE Mark to commercialize across Europe its first laser system in its class designed solely for use in treating glaucoma and its symptoms. The Cyclo G6 laser system is dedicated specifically to treat patients diagnosed with a range of glaucoma disease states and features the company's proprietary MicroPulse® tissue-sparing technology and a family of single use probes that connect to an intuitive, user-friendly laser console. "This regulatory approval marks a milestone for the glaucoma community and strengthens our portfolio to treat patients with difficult glaucoma conditions who need fast relief from uncontrolled eye pressure" said Dr. Keith Barton, Consultant Ophthalmologist, Glaucoma Service, Moorfields Eye Hospital, London, England. He continued, "Some studies of the Cyclo G6 have shown a 30-40% reduction in intraocular pressure (IOP) so this is a very promising therapy for our patients.
01/26/16 01:15 PMCoverage initiated on IRIDEX by Singular Research -
01/12/16 03:04 PMIRIDEX CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
01/11/16 03:04 PMIRIDEX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
01/11/16 05:47 AMIRIDEX Announces Preliminary Unaudited Revenues for 2015 Fourth Quarter and Full Year - [at noodls] - , /PRNewswire/ -- (Nasdaq:IRIX) today reported preliminary revenues of approximately $11.9 to $12.2 million and for the fourth quarter and full year 2015, respectively. Preliminary revenues in the fourth ...
01/08/16 11:00 AMEdited Transcript of IRIX earnings conference call or presentation 5-Nov-15 10:00pm GMT -
12/21/15 11:24 AMIRIDEX Corp. Earnings Analysis: Q3, 2015 By the Numbers -
12/08/15 12:17 PMIRIDEX CORP Financials -
12/02/15 07:30 AMTechnical Movement Driving Equities - Research on BIND Therapeutics, Edgewater Technology, IRIDEX, and PRGX Global - [Accesswire] - NEW YORK, NY / ACCESSWIRE / December 2, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: BIND Therapeutics ...
12/01/15 04:29 PMDo Hedge Funds Love IRIDEX Corporation (IRIX)? -
11/11/15 05:56 AMIRIDEX to Showcase Cyclo G6™ Laser System Equipped with MicroPulse® Tissue Sparing Glaucoma Technology at American Academy of Ophthalmology (AAO) Meeting - [at noodls] - IRIDEX to Showcase Cyclo G6™ Laser System Equipped with MicroPulse® Tissue Sparing Glaucoma Technology at American Academy of Ophthalmology (AAO) Meeting
11/10/15 04:05 PMIRIDEX CORP Files SEC form 10-Q, Quarterly Report -
11/05/15 05:48 PMIridex posts 3Q profit -

Social

About Iridex Corp.

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company's ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.

Industry, Sector and Symbol:
  • Sector: Computer and Technology
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: IRIX
  • CUSIP:
Key Metrics:
  • Previous Close: $16.21
  • 50 Day Moving Average: $15.21
  • 200 Day Moving Average: $11.83
  • P/E Ratio: 491.21
  • P/E Growth: 3.17
  • Market Cap: $163.19M
  • Beta: 0.72
Additional Links:
Iridex Corp. (NASDAQ:IRIX) Chart for Saturday, July, 30, 2016